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Background. 
The National Institute of Health and Care Excellence (NICE) in England and Wales 
recommends the combination of pharmacotherapy and psychotherapy for the treatment of 
moderate to severe depression. However, the cost-effectiveness analysis on which these 
recommendations are based have not included psychotherapy as monotherapy as a 
potential option. For this reason, we aimed to update, augment and refine the existing 
economic evaluation. 
 
Methods. 
We constructed a decision analytic model with a 27-month time horizon. We compared 
pharmacotherapy with cognitive behavioural therapy (CBT) and combination treatment for 
moderate to severe depression in secondary care from a healthcare service perspective. We 
reviewed the literature to identify relevant evidence and, where possible, synthesised 
evidence from clinical trials in a meta-analysis to inform model parameters. 
 
Results. 
The model suggested that CBT as monotherapy was most likely to be the most cost-
effective treatment option a cost per QALY threshold above £22,000. It dominated 
combination treatment and had an incremental cost-effectiveness ratio of £20,039 per 
quality-adjusted life year compared to pharmacotherapy. There was significant decision 
uncertainty in the probabilistic and deterministic sensitivity analyses. 
 
Conclusions. 
Contrary to previous NICE guidance, the results indicated that even for those patients for 
whom pharmacotherapy is acceptable, CBT as monotherapy may be a cost-effective 
treatment option. However, this conclusion was based on a limited evidence base, 
particularly for combination treatment. In addition, this evidence cannot easily be transferred 
to a primary care setting. 
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Introduction 
 
Depression is the most common psychiatric disorder. In 2007, 1.24 million people were 
estimated to suffer from this condition in England, which resulted in health and social care 
costs of £1.7 billion. By 2026, the number of people and costs associated with depression 
are projected to rise to 1.45 million and £3 billion, respectively (McCrone et al., 2008). 
Treatment for depression in the England and Wales is guided by a stepped-care model 
(NICE, 2009). Less intrusive and costly treatments such as guided self-help, physical 
exercise or computerised cognitive behavioural therapy are recommended for patients with 
sub-threshold or mild symptoms. Access to more intensive treatments (i.e. 
pharmacotherapy, psychotherapy and combination therapy) is indicated for patients who do 
not respond to or decline these options, or those presenting with more severe types of 
depression. In order to make best use of limited health care budgets, the evaluation of the 
relative cost-effectiveness of these three treatment alternatives has been a chief concern in 
the UK. Many studies assessing different types of antidepressants exist but comparisons 
between difficult treatment classes are less common. The fundamental question in this 
context is whether the added costs of psychotherapy, singly or in combination with 
pharmacotherapy, due to the more extensive contact with clinicians is outweighed by its 
potential benefits over pharmacotherapy. 
Current guidance by the National Institute for Health and Care Excellence (NICE) 
recommends the provision of a combination of pharmacotherapy and cognitive behavioural 
therapy (CBT) or Interpersonal psychotherapy (IPT) for both moderate and severe 
depression (NICE, 2009). However, this recommendation is based on an economic analysis 
that does not include psychotherapy in form of a monotherapy as a treatment alternative. 
The NICE (2009) guidance development group (GDG) justified this exclusion by noting that 
the “clinical evidence review showed no overall superiority for CBT alone on treatment 
outcomes” and that it had significantly higher treatment costs. Yet, elsewhere the GDG 
states that “it was not possible to identify a benefit of adding antidepressants to CBT”, and 
that “CBT alone was found to be better than antidepressant alone when compared with 
combined treatment”. In addition, in practice many patients in the UK do not appear to 
receive recommended treatments because of supply constraints in the provision of 
psychotherapy (Gyani et al., 2012). For these reasons, this study aimed to update and refine 
the available evidence on the comparative cost-effectiveness of treatments for depression to 
inform decision making in a secondary care setting. In particular, besides comparing 
pharmacotherapy and combination treatment we also included CBT monotherapy in the 
economic evaluation. 
  
Methods 
 
Patient population and comparators 
The target population of our decision analytic model were adults with moderate or severe 
major depressive disorder (MDD) according to cut-off scores on two common depression 
rating scales: the Hamilton Depression Scale (HAMD-17) (scores≥14) and the Beck 
Depression Inventory (BDI) (scores≥17) (American Psychiatric Association, 2000). Given the 
amount of available data, we chose to combine the available evidence base using a decision 
tree model. We included studies in which any antidepressant medication, face-to-face CBT 
or cognitive therapy and/or combination treatment were compared. We excluded other types 
of psychotherapies as they are not commonly available in the UK National Health Service 
and because to date less empirical evidence on them is available. We did not consider other 
forms of delivering psychotherapy such as group therapy or computerised CBT. We 
modelled treatment in a secondary care setting because the vast majority of patients in 
eligible studies recruited patients in this context. We only considered first line treatment and 
did not allow for treatment augmentation or switching during the acute treatment phase. 
 
Model structure 
None of the clinical trials relevant for our model followed up patients for more than 24 
months after the end of the acute treatment phase. Therefore, we compared the cost-
effectiveness of antidepressants, CBT and combination therapy over a 27-month time 
horizon consisting of 3-month acute treatment phase, a follow-up at 12 months and 24 
months after the end of acute treatment. We distinguished between three post-treatment 
clinical states or events: remission (or full response), response (or partial remission) and 
non-response.  
Premature termination of treatment is common in depression. In the model, patients were 
assumed to discontinue treatment because of positive reasons (i.e. remission or the 
perception thereof) or negative ones (i.e. no improvements in symptoms and/or side effects). 
Patients who remitted or responded to treatment were thought to be at risk of relapse in the 
follow-up phases of the model. Figure 1 shows the possible transition pathways of the 
model. 
 Event probabilities 
Where possible, we obtained data for model parameters from randomised controlled trials 
(RCTs) because they are believed to minimise the risk of bias (NICE, 2009). A regularly 
updated database by Cuijpers et al. (2008) contains a catalogue of RCTs that compare the 
effects of psychological treatments (both singly and in combination) in adults with depressive 
disorders with a control intervention. VD and LK independently screened the January 2013 
version of this database to identify relevant head-to-head comparisons. We included English 
language studies only. 
We extracted data on remission, response and dropout rates if the study reported these 
outcomes at completion of the acute treatment phase. We considered patients with a score 
of 7 or less on the HAMD-17 to be in remission, those reaching a score between 8 and 13 to 
be responders and those with a score of 14 or above as non-responders (NICE, 2009). 
However, we allowed for a ±1 point margin in the cut-off definitions due to slight variations 
between studies. We extracted the data on an intention to treat basis. For consistency with 
NICE (2009) guidelines, we only extracted data on relapse rates from trials that incorporated 
some form of maintenance treatment, i.e. pharmacotherapy had to be continued beyond the 
end of the acute phase and ‘booster’ sessions had to available to patients both in the 
monotherapy and combination therapy arms. In light of the small number of studies that met 
this criterion, we allowed for any definition of relapse and allowed for studies that included 
some patients that may have been responders but not remitters according to our definition. 
In practice, in all included trials pharmacotherapy was discontinued at 6 or 12 month after 
remission. Based on our knowledge of the disease area and for sake of clarity, we 
considered it to be most appropriate to take a ‘worst-case scenario’ approach to missing 
data (Higgins and Green, 2008). In other words, we assumed that patients with a missing 
endpoint assessment in the acute and follow-up phase would be in the least favourable 
health status (i.e. non-response or relapse) and if it was unclear at what point patient 
dropped out of the study during the post-acute follow-up, we assumed that this occurred 
before the first-follow up. There appeared to be some ambiguities in how the data was 
reported in the follow-up studies. Given the importance of relapse rates for the results of the 
model, we individually comment on our approach to relapse rate data extraction in Appendix 
C. 
We were unable to identify randomised trials that compared relapse rates among patients 
responding to treatment in isolation from remitters according to our definition of these 
subgroups. For this reason, over the first twelve months of follow-up, for the 
pharmacotherapy arm in our model we used the relapse rate of patients with a HAMD-17 
score between 8 and 13 in the trial by Kuyken et al. (2008) who were treated with 
antidepressants. Conditional on not having relapsed until this point, we assumed that the 
relapse rate among pharmacotherapy treatment responders over the second 12 month 
follow-up was the same as among remitters. It appeared plausible that the direction of 
relative differences in relapse rates between treatments in terms of protecting against 
relapse would be the same among patients who were in remission after the acute treatment 
phase as for those responding to treatment. In absence of any direct evidence to support 
this belief or data on the relative magnitude of effects, we adopted a conservative approach 
aimed to reflect this notion in our model without unduly favouring any of the three 
interventions. Specifically, we assumed that the risk differences in relapse rates between the 
three interventions would be the same as among remitters but multiplied by a discount factor 
with mean 0.5 and standard deviation 0.3, i.e. reduced by 50% on average. 
A priori, there were clinical reasons to believe that some heterogeneity in observed 
treatment effects would be present. Besides the fact that different types of antidepressants 
were included in our comparisons, there is considerable variability in how both 
psychotherapy and pharmacotherapy are implemented in trials. Therefore, we synthesised 
the evidence using random-effects meta-analyses which does not assume the presence of a 
common effect across all studies (Borenstein et al., 2009, Riley et al., 2011). We adapted a 
Bayesian network meta-analysis framework proposed by Dias et al. (2013a) which accounts 
both direct and indirect treatment effects and correlations between arms within a trial. To 
better reflect the uncertainty resulting from heterogeneity between trials in a decision making 
context, we used predictive rather posterior distributions for baseline rates and treatment 
effects in our model (Dias et al., 2013b, Dias et al., 2013c). In other words, we modelled the 
uncertainty surrounding a hypothetical future ‘roll out’ of the interventions given the between-
study variance rather than the uncertainty surrounding the average presumed underlying 
treatment effects. We applied vague prior distributions for baseline and weakly informative t 
family priors to treatment effects (Gelman et al., 2008). For between-study variances, on the 
other hand, we used an informative prior distributions based on a review by Turner et al. 
(2012) to stabilize our estimates. Put differently, when there were few studies available to 
inform the estimate of between study variance, such as in the follow-up phase, we assumed 
that variance between studies in our meta-analysis would be relatively similar to that in 
comparable meta-analyses in the literature rather than relying on the limited amount of 
existing data, whereas we allowed the data to ‘dominate’ when sufficient evidence was 
available. We used WinBUGS to run our analyses. The code which allows the replication of 
the entire decision model including these meta-analyses can be found in Appendix D. 
The literature contained little systematic evidence on the disease course of patients who 
discontinued depression treatment. Data by Radhakrishnan et al. (2013) as well as expert 
opinion elicited by NICE (2009) and Sado et al. (2009) suggested that approximately 20% of 
patients discontinue treatment due to recovery and this figure was used. We assumed that, 
regardless of initial treatment assignment, relapse rates at 12 month follow-up among 
patients who discontinued treatment because of feeling cured was equal to those of patients 
treated with a placebo during the acute phase in a study by Jarrett et al. (2000). In addition, 
we assumed that patients in this subgroup who which did not relapse of during the first 12 
month follow-up were not at risk of relapse over the remaining time horizon of the model. 
 
Health-related quality of life 
We quantified the health benefits of the interventions using quality adjusted life years 
(QALYs). This approach assigns a preference-based weight, usually between 1 
(representing full health) and 0 (representing death) to health states in an attempt to quantify 
the relative value of quality of life therein. This value is multiplied by the length of time spent 
in that health state to yield QALYs (Malek, 2000). The EuroQol 5 Dimensions (EQ-5D) is the 
instrument currently preferred by NICE to derive the preference weights for health states in 
adults (NICE, 2013). However, a review of the literature suggested that no published 
evidence was available mapping EQ-5D scores by depression status as defined by the 
HAMD-17 in this model. Therefore, we calculated mean EQ-5D utilities for remitters, 
responders and non-responders as defined above ourselves using data from a trial by 
Kuyken et al. (2008) on patients with recurrent depression. To account for the fact that 
repeated measures were available for most patients, we used a pooled ordinary least 
squares model with cluster robust standard errors. We assigned the same quality of life to 
patients dropping out of treatment due to side effects or no response as to those who 
completed the treatment but who did not respond. 
 
Costs 
We measured costs from a UK health care perspective and used a price year of 2012. Due 
to lack of robust empirical evidence, we based our costing for the interventions on a 
assumptions made in a previous cost-effectiveness analysis by Simon et al. (2006) using 
unit cost data from Curtis (2012). Since it was the most widely prescribed antidepressant in 
England in 2010, pharmacotherapy was assumed to consist of a 20mg daily dose of 
citalopram over a for a total of 15 months (Ilyas and Moncrieff, 2012). This is longer than 
treatment period than suggested by NICE (2009) guidance but consistent with the RCTs 
informing our model. As part of patient monitoring beyond what would be expected in usual 
care, patients treated with antidepressants were initially assumed to have two appointments 
with a psychiatric consultant and two with a specialist registrar each lasting 50 minutes. 
(NICE, 2009). CBT treatment was assumed to consist of 16 sessions during the acute 
treatment phase and two additional ‘booster’ sessions after that. We assumed that patients 
who discontinued pharmacotherapy dropped out of treatment after one month of treatment 
and one appointment with a psychiatric consultant whereas patients receiving CBT were 
assumed to drop out after four sessions. The cost for combination therapy in our model was 
the sum of the cost of pharmacotherapy and psychotherapy. We assumed that patients who 
did not respond to the treatment administered in the acute phase would not receive any 
booster CBT sessions and/or maintenance pharmacotherapy. 
We obtained estimates of health care resource use by depression status from the same 
study that provided the EQ-5D data (Kuyken et al., 2008) and again used a pooled ordinary 
least squares model with cluster robust standard errors in our estimation of these figures. 
We updated the costs from this study using the Hospital and Community Health Service Pay 
and Price Index (Curtis, 2012). To reflect the current value of the benefits and costs 
accumulating over the time horizon of the model we discounted both at a rate of 3.5% as 
suggested by NICE (2013). Table 1 summarises the model inputs that were not estimated in 
the meta-analyses. 
 
Cost-effectiveness and sensitivity analyses 
We calculated incremental cost-effectiveness ratios (ICER) by dividing the estimated mean 
differences in costs between two treatments by the mean difference in QALYs. To address 
uncertainty in the ICERs we undertook a probabilistic sensitivity analysis. This involved 
repeatedly simulating random draws from the distribution of the parameter inputs in order to 
determine the joint distribution of the outputs of the model (i.e. the relative mean cost and 
effects of the interventions). We displayed these distributions on a cost-effectiveness plane 
as credible ellipses. These regions indicate the ‘true’ cost-effectiveness estimates are likely 
to lie in and can thus be considered to be a two-dimensional generalisation of credible 
intervals. 
Given the replications generated by the simulations, it was also possible to determine the net 
benefit of each intervention in each of the replications using the formula 𝑁𝐵 = 𝜆 ∙ 𝐸 − 𝐶, 
where 𝐶 were the costs of the intervention, 𝐸 the benefits of the intervention in QALYs and 𝜆 
the value placed on a QALY by decision makers. We then determined the proportion of 
replications where each of the interventions had the highest net benefit (i.e. the probability 
that they were the most cost-effective). We displayed these data for a range of 𝜆 using cost-
effectiveness acceptability curves (CEACs) (Fenwick and Byford, 2005). Values of the CEAC 
close to 1 or 0 indicated that the uncertainty as to whether the respective treatment was 
most likely to be the most cost-effective was low (Baio, 2012). In this study, we discuss the 
results for a range of 𝜆 between £20,000 to £30,000 because this has been presumed to be 
the range of willingness to pay for QALY improvement by the NICE but we acknowledge that 
lower estimates have recently been suggested (Haycox, 2013). 
We undertook four sensitivity analyses that had the potential to affect the results of the 
model. First, we considered the impact of relaxing the inclusion criteria for studies to be 
included in the meta-analysis of acute phase data. Unlike previous economic models, we 
focused exclusively on trials assessing CBT or CT. For that reason, amongst others, in our 
base case meta-analysis we excluded of a large trial by Keller et al. (2000), which assesses 
the efficacy of Cognitive Behavioural-Analysis System of Psychotherapy (CBASP). CBASP 
shares some of the features of CBT but differs from the way that it is commonly implemented 
due to its primary focus on interpersonal interactions (Driessen and Hollon, 2010). However, 
due to the size of this study, in our first sensitivity analysis we analysed the effect of 
including Keller et al. (2000). Second, the costing assumptions with respect to CBT in our 
base case scenario was likely to favour pharmacotherapy because typically patients tend to 
attend fewer appointments than set out in this treatment protocol even if completing 
treatment. In the studies included in the meta-analysis attendance rate was approximately 
80%. It was unclear what fraction of unattended session was cancelled without prior notice 
but to gain some understanding of the potential implications of non-attendance we reduced 
psychotherapy costs by 20% in our second sensitivity. Third, we relaxed the inclusion criteria 
for the follow-up period, incorporating studies in our meta-analysis in which drug treatment 
was provided after the end of the acute phase in the pharmacotherapy arm but not 
necessarily any maintenance treatment in the other two arms. Finally, we used SF-6D utility 
data from Kendrick et al. (2009) to assess the sensitivity of the estimated QALY gains to the 
choice of utility measure. As in the case of EQ-5D, we used a pooled ordinary least squares 
model with robust standard errors to estimate the mean utility scores.  
Results 
 
We identified fifteen randomised trials that fulfilled our inclusion criteria for the acute phase. 
Eleven of these compared pharmacotherapy with CBT as a monotherapy, three compared 
pharmacotherapy with both CBT and combination treatment, and one compared CBT with 
combination treatment only. We report the raw data extracted from these studies in 
Appendix C. Figure 2 summarises the results of the meta-analysis at the end of the acute 
treatment phase and the meta-analyses at the two follow-ups. CBT and combination therapy 
both had higher proportion of patients remitting and a lower proportion of patients 
discontinuing prematurely than pharmacotherapy. Patients were more likely to complete 
CBT treatment than combination therapy, but the share of individuals whose depression 
status improved was similar. The probability of remission was higher under combination 
treatment than CBT. In the base case scenario, only three trials fulfilled our inclusion criteria 
for the follow-up phase, one of which included combination therapy. At 12 month follow-up 
the risk of relapse among remitters was estimated to be lowest for CBT (43%), followed by 
combination therapy (49%) and pharmacotherapy (55%). The ranking of cumulative relapse 
rates was the same at 24 month follow-up with probabilities of 62%, 66% and 75% 
respectively (see Figure 2). Forest plots for all meta-analyses can be found in Appendix B. 
The model suggested that pharmacotherapy and combination therapy had the lowest and 
highest expected costs respectively (£3645 vs. £5060). The estimate for CBT was £4418. 
QALYs were lowest in the pharmacotherapy arm (1.236), whereas those for CBT and 
combination treatment were identical up to a rounding error (1.274). Therefore, CBT yielded 
the same benefits as combination therapy while being less expensive, i.e. CBT dominated 
combination therapy. The ICER for CBT compared to pharmacotherapy was £20,039/QALY 
(Table 2). Figure 3 shows CEACs comparing all three treatments at the same time. Within 
the aforementioned NICE threshold range there was much uncertainty. At the lower end, 
pharmacotherapy, the least expensive treatment, was most likely to be cost-effective, 
whereas at a threshold above around £22,000 per QALY this changes to CBT. There was 
considerable decision uncertainty because there was a strong chance of not choosing the 
most cost-effective treatment option when deciding on the treatment with the highest 
average net benefit, i.e. pharmacotherapy at a willingness to pay of less than £20,039 and 
CBT above that. Figure 3 also shows that combination treatment was least likely to be cost-
effective with the range of £20,000 to £30,000 per QALY. The estimated probability ranged 
from 15 to 23%. 
Table 2 shows the results of the sensitivity analyses. As previously mentioned, to simplify 
comparison between the scenarios, we also display the estimated cost and effect differences 
for each of these graphically using cost-effectiveness planes in Appendix A. Including the 
study by Keller et al. (2000) in the meta-analysis substantially increased the cost-
effectiveness of combination treatment, such that it became the treatment most rather than 
least likely to be cost-effective. However, the decision uncertainty between the three 
treatment options remained high in this scenario. As indicated in Table 2 at a willingness to 
pay of £25,000 per QALY, the probabilities of pharmacotherapy (32%), CBT (31%) and 
combination treatment (37%) being the most cost-effective treatment were comparable. As 
expected, reducing the CBT attendance rate in the second sensitivity analysis lowered the 
costs of both CBT monotherapy and combination treatment. This did not affect the ranking of 
treatments in terms of their cost-effectiveness but the ICER for CBT was considerably lower 
at £9,714 per QALY in this scenario. In the third sensitivity analysis, two additional studies 
were included in the meta-analysis of relapse rates. As a result, rather than CBT, relapse 
rates in were estimated to be lowest with combination therapy. However, the additional 
QALY gain of combination treatment over CBT was not sufficient to make it the treatment 
with the highest likelihood of being cost-effective and at £61,403 per QALY the ICER for 
combination therapy relative to CBT was high. Using SF-6D instead of EQ-5D to estimate 
QALYs decreased the absolute differences in QALYs between the treatments such that the 
ICER for CBT increased to £32,582 per QALY and at a willingness to pay for a QALY of 
£25,000 pharmacotherapy became the treatment most likely to be cost-effective (51% 
probability). In summary, two sensitivity analyses affected the ranking of the interventions in 
terms of the probability of being the most cost-effective compared to our base case scenario 
and the ICERs for the interventions varied markedly between the scenarios under 
consideration. 
 
Discussion 
 
This study adds to the existing economic evaluations comparing psychological and 
pharmacological treatments for depression. Specifically, two decision models commissioned 
by NICE exist examining a comparable decision problem as our study. However, these 
analyses come to different conclusions than our appraisal of the evidence. NICE (2009) 
reported ICERs of £7,052 and £5,558 per QALY respectively for combination therapy 
relative to pharmacotherapy in the treatment of moderate and severe depression in 
secondary care. In the related study Simon et al. (2006) the corresponding ICERs were 
£4,056 and £14,540 per QALY. By contrast, our analysis suggested that CBT as 
monotherapy was more likely to be cost-effective than pharmacotherapy which in turn was 
more likely to be cost-effective than combination treatment. In addition, the decision 
uncertainty was much greater in our model, i.e. the difference in the probability of being cost-
effective between the treatments as suggested by the CEACs was lower. 
These discrepancies are largely due to four differences in the modelling approach. First, we 
specified different inclusion criteria than these earlier studies. For example, we excluded 
data by Simons et al. (1986) which suggested a large difference in relapse rates between 
pharmacotherapy and combination therapy because, contrary to NICE guidance, treatment 
was discontinued in this study following the end of the acute phase. Also, we restricted our 
analysis to studies on CBT or CT rather than allowing for all types of psychotherapies. In our 
sensitivity analysis we showed that excluding the trial by Keller et al. (2000) which reported 
large benefits of combination treatment over the two monotherapies for a type of 
psychological therapy that is not commonly provided in the NHS has a significant effect on 
the cost-effectiveness estimate of combination treatment. Second, we used more modern 
methods of evidence synthesis. As a result, for example, when comparing the effect of 
pharmacotherapy and combination therapy on remission rates, the network meta-analysis 
estimates are smaller than those in a traditional pairwise analysis because it accounts for the 
fact that in trials including all three treatments, the treatment effect for CBT was above 
average compared to the trials which did not include combination treatment. In statistical 
terms, it accounted for trial arms not missing completely at random. Third, the time horizon 
of the study was extended beyond 15-month. This particularly improved the cost-
effectiveness of CBT since, at least in the base case scenario, the meta-analysis suggested 
that was superior to the other two treatments in preventing relapse. Fourth, our model was 
based on different health states and disease trajectories. For example, we differentiated 
between patients showing full and partial response rather than implicitly assuming that all 
patients who did not remit showed no response. On the other hand, we considered the 
information reported in clinical trials to be too limited to differentiate between the treatment 
effects for patients with moderate depression and those with severe depression at baseline. 
Instead, we modelled the cost-effectiveness for these two populations as a whole. 
Besides these differences in the cost-effectiveness estimates, we would also argue that the 
conclusions that can be drawn from the results of our economic model and its predecessors 
are more limited than implied by NICE (2009) guidelines. Current recommendations do not 
differentiate between treatment in a primary and secondary care setting but the vast majority 
of the data used to inform the parameters in this model as well as the analyses by NICE 
(2009) and Simon et al. (2006) draw from the clinical literature set in secondary care. One 
would expect depression severity and general health status of patients to be worse in this 
setting and there are also likely to be different implications for resource use than in primary 
care. Therefore, we would argue that the conclusions drawn from this model cannot easily 
be transferred to treatment of depression in primary care, the setting in which most patients 
with depression are cared for in the UK. The differences between the results of this model 
and its predecessors do, however, illustrate the fragility of cost-effectiveness estimates in the 
depression. Given investments of over £400 million to increase the availability of 
psychological treatments in primary care as part of the improving access to psychological 
therapies (IAPT) initiative, this also highlights the need for further examination of the 
economic evidence for treatment of depression in UK primary care (Clark, 2011, Department 
of Health, 2012). 
We invite the reader to critically examine our choice of inputs, synthesis method, model 
structure and the validity of the conclusions drawn in light of the available evidence (Afzali et 
al., 2012a, b). Decision models can be useful in synthesising, linking and extrapolating a 
wide variety of information in a transparent fashion, but they are inevitably reductionist and 
can only be regarded as decision aids (something that could be also argued to apply to 
RCTs). In the appraisal of the evidence base, modellers are faced with an inevitable trade-
off between competing objectives such as precision, relevance, validity and feasibility. This 
model is no exception from most other health economic models in that it is heavily 
dependent on structural assumptions, i.e. it largely omits non-statistical uncertainty (Grutters 
et al., 2014). 
Our meta-analyses combined heterogeneous treatments to yield a single treatment effect 
estimate. Thus, rather than taking the ‘best’ antidepressant as the relevant benchmark, as 
was the case in NICE (2009) and Simon et al. (2006), we evaluated pharmacotherapy and 
combination therapy as a class which may have biased results to some extent. Similarly, 
both in psychological therapy and pharmacotherapy, variations in non-specific elements, 
treatment fidelity and the therapeutic relationship across studies are likely to have some 
bearing on treatment effectiveness which may have been a source of bias. However, there 
was a dearth of evidence with respect to some model parameters, particularly response and 
relapse rates in combination therapy. Therefore, we believe that our approach was 
preferable to applying of further quality criteria as this would have further reduced the 
robustness of the model or required additional subjective judgements. Unlike previous 
studies, we consistently used the HAM-D as the backbone of the model to enhance the 
internal consistency of the model, however, to do so it was necessary to derive key model 
parameter estimates from a single trial carried out in a primary care setting (Kuyken et al., 
2008). Since patients in primary care are likely to consume less health care resources 
beyond the resources used for depression treatment, this is likely to have underestimate the 
cost-effectiveness of the more effective treatments, i.e. combination treatment and CBT, to 
some extent. Furthermore, the psychometric properties of HAM-D have been debated and 
may have biased our comparison (Fountoulakis et al., 2014). This study applies more 
modern statistical methods to estimate parameters and account for uncertainty than its 
predecessors, but, amongst others, a limitation which remains in our meta-analysis is the 
assumption that there is no correlation in outcomes within treatment arms which is unlikely to 
hold. 
Another feature of our model that should be emphasised is that, like its precursors, the 
efficacy of the interventions was based primarily on RCT data given its status in the NICE 
hierarchy of evidence and because adequate observational data was not available. Yet, this 
also represents a limitation of this study because the generalisability of RCTs in depression 
to routine clinical practice has been questioned (van der Lem et al., 2012). Since reporting 
on side effects, suicide risks and the exact timing of events in these trials is inconsistent or 
incomplete, this also meant that we did not incorporate these into the decision model. The 
exclusion of adverse drug reactions evidently favoured pharmacotherapy and combination 
therapy but there does not appear to be clear evidence to indicate what the direction of bias 
in our model might be because of the omission of other two factors. In addition, in all 
relevant RCTs antidepressants were tapered off after 6 or 12 months follow-up for all 
patients in the pharmacotherapy and combination treatment arm. However, due to increased 
risk of relapse after withdrawal from medications, NICE (2009) guidelines advise 
continuation of antidepressant treatments for longer than that for at risk patients which is 
increasingly the case in routine clinical practice (Moore et al., 2009). It is unclear what effect 
this discrepancy between naturalistic and trial prescribing practice might have on the relative 
cost-effectiveness of pharmacotherapy and combination treatment. We would also like to 
emphasise that, at best, data from RCTs only applies to individuals who are likely to 
participate in them. Some patients treated for depression in secondary care are likely to be 
so unwell that they are unlikely to be enrolled in a typical trial and in practice many patients 
with MDD have strong preferences for pharmacotherapy or psychotherapy which should be 
taken into account in the choice of treatment for depression (NICE, 2009, van Schaik et al., 
2004). 
 
 
 
Conclusion 
 
In this paper we have revisited the evidence base for treatment of depression in UK 
secondary care. Our economic appraisal differs from the recommendation made by current 
NICE (2009) guidance and our decision model may therefore be of use when reviewing 
treatment recommendations for depression in the future. In a routine care setting, local 
consideration and the constraints in the supply of CBT are likely to play a role in treatment 
decisions, but this model may offer a platform for further discussion of the cost-effectiveness 
of interventions (Gyani et al., 2012). We found the evidence base comparing 
pharmacotherapy, CBT and combination therapy for depression to be remarkably limited, 
particularly with respect to the latter. Thus, besides further economic evaluations in UK 
primary care, we would like to suggest three areas of uncertainty that, we believe, would 
particularly warrant more in depth exploration. First, the relative cost-effectiveness of 
different types of interventions for depression is likely to differ between subgroup of patients. 
Personalising the choice of treatment will be critical to more efficient use of health care 
resources in the future (Cuijpers et al., 2012, Hollinghurst et al., 2014, Simon and Perlis, 
2010, Wallace et al., 2013). Second, we would encourage the use of observational data 
coupled with appropriate statistical methods to gain a better understanding of the effects of 
depression treatment in a routine care setting and the long-term cost-effectiveness. Third, 
the wider societal impact of depression treatments and the way that it should be 
incorporated into health technology assessment is currently unclear due to a host of 
methodological, ethical, policy and practical issues (NICE, 2014, Sculpher, 2001). However, 
recent evidence suggests that CBT may produce greater improvements in employability 
which warrants further exploration (Fournier et al., 2014). 
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